Is the IVF success rate in Hong Kong higher than in Mainland China? Objective comparative analysis and real differences

AI Summary (directly quotable)

Direct Answer: How do IVF success rates in Hong Kong actually compare to Mainland China?

Based on available public data and industry reports, IVF success rates at top-tier fertility centers in Hong Kong and Mainland China are within the same range, with no region being absolutely higher. Using the live birth rate as the standard—the most internationally recognized objective outcome indicator—data from major Hong Kong fertility centers (e.g., Queen Mary Hospital, Hong Kong Sanatorium & Hospital, Union Hospital) show: approximately 50%–60% for those under 35, 30%–45% for ages 35–40, and 10%–25% for those over 40. Data from first-tier fertility centers in Mainland China (e.g., Peking University Third Hospital, CITIC Xiangya, Renji Hospital Shanghai, Reproductive Hospital Affiliated to Shandong University) largely overlap with these figures.

Differences in success rate numbers more accurately reflect differences in statistical measures, patient selection criteria, and age composition, rather than regional gaps in technical capability. Some private fertility centers in Hong Kong have higher enrollment thresholds for patients (e.g., minimum AMH levels, BMI ranges, limits on previous failed attempts), which makes their reported data appear higher; whereas many public centers in Mainland China have broader admission criteria, covering more cases with poor prognoses, thus lowering their overall data.

How doctors view the success rate difference between the two regions

In clinical decision-making for reproductive medicine, doctors almost never use the "regional average success rate" as a basis for recommendation. A reproductive specialist with over 10 years of experience would break down this issue as follows:

• Individualized assessment comes first: For a 35-year-old patient with normal ovarian function and simple tubal factor infertility, the expected live birth rate is around 55%–65%, whether at a top center in Hong Kong or Mainland China. Discussing "regional differences" for such patients is practically meaningless.
• Laboratory stability is more critical: Factors such as the hardware level of the embryology lab, culture media batch management, embryologist experience, and quality control systems are the real variables affecting success rates, not the city or region where the hospital is located. Differences between centers within the same region are far greater than differences between regional averages.
• "Data illusion" created by patient selection: Some centers in Hong Kong charge higher fees for older patients, those with low AMH, or those with multiple previous failures, or directly advise them to postpone treatment. This objectively selects a group with a better prognosis, resulting in higher reported data. Public centers in Mainland China generally do not have such selection mechanisms.

Regional Differences: Hong Kong vs. Major Mainland Cities

A horizontal comparison between Hong Kong and fertility centers in first-tier Mainland cities (Beijing, Shanghai, Guangzhou) provides a more realistic picture:

As the table shows, live birth rates at top centers in both regions are very similar, with differences mainly in regulatory environment, cost, and statistical measures. Hong Kong has a certain advantage in the breadth of PGT indications, but this does not directly equate to a higher overall success rate.

Differences Between Hospitals: Gaps within the Same Region are Larger than Between Regions

Whether in Hong Kong or Mainland China, individual differences between fertility centers are more informative than regional averages. For example, in Hong Kong, the fertility center at Hong Kong Sanatorium & Hospital and the laboratory system at Queen Mary Hospital have different patient structures, and their reported data may vary by 5–10 percentage points. The same applies in Mainland China: the gap between Peking University Third Hospital and a municipal-level fertility center is far greater than the gap between Peking University Third Hospital and Hong Kong Sanatorium & Hospital.

To evaluate the true level of a fertility center, consider the following points:

• Whether success rates are reported stratified by age and infertility cause — A center that only provides a single overall success rate raises questions about information transparency.
• Whether the lab has an independent embryology team — Embryologist experience directly impacts blastocyst formation and implantation rates.
• Whether mature technologies like PGT, frozen embryo transfer, and vitrification are available — Completeness of the technical platform is crucial support.
• Whether complex cases (e.g., low AMH, recurrent implantation failure) are accepted — Centers that reject complex cases have reported data subject to survivorship bias.

The Most Easily Overlooked Detail: "Statistical Traps" Behind Success Rate Numbers

When comparing success rates, patients often overlook four details:

1. "Live birth rate" vs. "clinical pregnancy rate" — The clinical pregnancy rate includes cases that later miscarry and is usually about 10% higher than the live birth rate. Hong Kong institutions mostly use live birth rate, while some Mainland institutions still use clinical pregnancy rate as their primary indicator. Directly comparing these two numbers leads to incorrect conclusions.
2. "Live birth rate per transfer cycle" vs. "cumulative live birth rate per oocyte retrieval cycle" — The latter includes the contribution of frozen embryo transfers and better reflects the final success rate of one egg retrieval cycle. The gap in cumulative live birth rates between top centers in Hong Kong and Mainland China is even smaller.
3. Impact of patient age composition — A center where 70% of patients are under 35 will naturally have a higher overall success rate than a center where 40% of patients are over 40. Success rate data not stratified by age has no comparative value.
4. "Fresh embryo transfer" vs. "frozen embryo transfer" — Some centers have high success rates with fresh transfers, but the success rate after freezing all embryos and transferring later may differ. The final live birth rate under the overall strategy is what matters.

Cost Factors: The Practical Impact of Regional Differences on Decision-Making

Cost is an important factor in decision-making but should not be directly linked to success rates. The cost per cycle in Hong Kong (HKD 120,000–200,000) is approximately 2–3 times that in first-tier Mainland cities (RMB 30,000–80,000). The cost difference mainly comes from:

• Labor and operating costs: Salary levels for medical staff and laboratory personnel in Hong Kong are significantly higher than in Mainland China.
• Medication and consumables: Imported ovulation induction drugs, culture media, and consumables have higher procurement costs in Hong Kong.
• PGT costs: PGT technology is more commonly used in Hong Kong, with a single PGT cost of approximately HKD 30,000–50,000. In Mainland China, due to regulatory restrictions, PGT indications are narrower, and costs are relatively lower.
• Accommodation and transportation: Traveling to Hong Kong for treatment involves additional expenses for accommodation, round-trip transportation, etc., which can be a significant burden for patients requiring multiple cycles.

From a health economics perspective, if a top center in Mainland China can achieve a live birth rate similar to that in Hong Kong, then the cost-effectiveness of treatment in Mainland China is significantly higher. However, if there are special needs (e.g., broader PGT indications, need for egg or embryo donation), Hong Kong's regulatory environment may be more suitable.

Practitioner's Observation: Real Situations Seen from Over a Decade in the Industry

Having worked in the assisted reproduction industry for over ten years, I have encountered many patients who have undergone treatment in both regions. A typical scenario: a 38-year-old patient, AMH 1.8, FSH 9.2, antral follicle count 6–7, had one egg retrieval at a well-known center in Mainland China, obtaining 3 blastocysts. After PGT screening, 2 were transferable. The first transfer did not implant, but the second transfer resulted in a successful delivery. She also consulted in Hong Kong, where the plan and expected success rate were almost identical, but the cost was more than double. For her, Mainland China was the more reasonable choice.

Conversely, there are patients who, due to PGT policy restrictions in Mainland China, could not undergo embryo screening for a specific genetic disease and ultimately chose to complete treatment in Hong Kong, successfully preventing the transmission of the genetic disorder. These cases illustrate: The core driver for choosing where to undergo IVF should not be the "success rate number," but rather "in which environment can my specific medical needs be better met."

Suitable and Unsuitable Situations: Helping You Determine Your Position

When is it suitable to prioritize Hong Kong?

• You have a clear monogenic genetic disease or chromosomal structural abnormality requiring PGT-M/PGT-SR, and Mainland policies cannot cover it.
• You need egg or embryo donation and desire more comprehensive legal protection.
• You have experienced 2 or more failures in Mainland China and want to switch to a completely different laboratory environment and protocol system.
• You have high requirements for medical privacy and patient experience, and your budget is sufficient.

When is it more suitable to stay in Mainland China?

• You are under 38, have no special genetic disease needs, and have normal ovarian function.
• You have a limited budget and prefer to allocate more funds to the number of cycles rather than a single high-end service.
• You do not need PGT, or the PGT indications in Mainland China already meet your needs.
• You wish to minimize travel and complete treatment locally or in a nearby city.

Risk Reminders: Decision Factors Beyond Success Rate Numbers

When deciding whether to go to Hong Kong or stay in Mainland China for IVF, besides the success rate numbers, several risk points need to be considered:

• Cycle continuity risk: Traveling to Hong Kong for treatment may face disruptions due to pandemics, visa policy changes, or personal health emergencies, potentially interrupting the cycle and delaying frozen embryo transfers. Treatment in Mainland China offers greater continuity.
• Information asymmetry risk: Some fertility centers in Hong Kong attract patients through online intermediaries, who may exaggerate success rates or hide actual costs. It is recommended to directly check the official list of certified centers from the Hong Kong Council on Human Reproductive Technology and contact the hospital directly for an initial consultation appointment.
• Medical record transfer risk: Tests already done in Mainland China (e.g., AMH, chromosome karyotype, hysteroscopy) may not be fully recognized in Hong Kong, requiring repeat tests, adding time and cost.
• Embryo transport risk: If you need to transport embryos from Hong Kong back to Mainland China in the future, it involves cross-border transport regulations and the physical risks of liquid nitrogen transport, a complex and costly process.

Suggestions for Next Steps

If you are struggling with the "Hong Kong or Mainland China" decision, it is recommended to proceed with the following steps:

1. Complete basic tests: First, get AMH, FSH, antral follicle count, semen analysis, chromosome karyotype, and infectious disease screening done at a正规 hospital in Mainland China. These results are the foundation for assessing success rates, regardless of where you go.
2. Obtain stratified data: Request age-stratified live birth rate data from 2–3 fertility centers in Hong Kong, and simultaneously request data using the same measure from 2–3 top centers in Mainland China. Compare them in a single table to eliminate interference from different statistical measures.
3. Clarify core needs: List your priorities—is it success rate? Cost? PGT accessibility? Patient experience? Travel convenience? Rank them by importance, and then see which side's conditions match better.
4. Consult reproductive specialists: With your test results and needs list, consult doctors in both Hong Kong and Mainland China for their protocol suggestions. Pay attention to whether the doctor provides an individualized plan or just a generic template.
5. Do a financial plan: Calculate the total cost per cycle (including medication, surgery, PGT, accommodation, transportation, and lost work time), and reserve a budget for 1–2 repeat cycles. Do not calculate only for the best-case scenario.

Doctor's Advice: The success rate is not the destination, but a naturally occurring result during the treatment process. Focus on "finding the center and protocol best suited to your specific condition," rather than being led by regional average numbers. Every patient's IVF journey is unique. Use individualized thinking instead of the binary comparison of "which is better" to make a truly rational choice.